Drug Trial Radar · NCT05927597
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants
Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Jan 9, 2019
Primary completion
Aug 1, 2019
Study completion Aug 1, 2019
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of Part A of this study is to compare, in a single dose and multiple doses the safety, tolerability, and pharmacokinetics (PK) profile administered in Japanese and Caucasian participants and of Part B of the study is to assess the food effect of a single dose of INS1007 administered in Japanese and Caucasian participants.
Conditions
- Healthy Volunteers
Interventions
INS1007Drug
Oral tablets.
PlaceboDrug
Oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Number of Participants Who Experienced at Least One Adverse Event (AE)Time frame: Up to Day 61 in Part A and up to Day 11 in Part B
- Parts A and B: Area Under the Plasma Concentration-time Curve (AUC) of INS1007Time frame: Part A: Predose and at multiple time points postdose up to Day 33; Part B: Predose and at multiple time points postdose up to Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USA001
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.